Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
Related Experiment Video
Updated: Dec 8, 2025
Lidong Liu1,2,3, Zhiwei Zhang1, Guoxiang Zhang1
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, Shandong, People's Republic of China.
Background:
Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biological role of PADI2 in ovarian cancer (OC) and the relative mechanism.
Methods:
Gene Expression Profiling Interactive Analysis (GEPIA) ( https://gepia.pku.cn/ ) and ONCOMINE ( https://www.oncomine.org/ ) were used to analyze PADI2 Gene Expression data. The survival curve for the PADI2 gene was generated by using the online Kaplan-Meier mapping site ( https://www.kmplot.com/ ). We conducted MTT assay, cloning formation assay and EdU cell proliferation assay to detect the cell activity of PADI2 knockdown A2780 and SKOV3 ovarian cancer cells treated with Olaparib. Cell migration and invasion were observed by would healing and transwell assay. The pathway changes after the treatment of PADI2 were detected by transcriptome sequencing and western blot. The role of PADI2 combined with Olaparib treatment in vivo was studied in nude mouse model bearing ovarian cancer tumor.
Results:
We investigated the role of PADI2 on EOC in vitro and in vivo. PADI2 was upregulated in ovarian cancer samples and high PADI2 expression was correlated with poor outcome. Downregulating PADI2 suppressed colony formation, proliferation, migration and invasion of A2780 and SKOV3 cells. Furthermore, downregulating PADI2 and Olaparib combination treatment attenuated the viability, migration and invasion of A2780 and SKOV3 cells. We identified differentially expressed genes in A2780-shPADI2 and SKOV3-shPADI2 cell by transcriptome sequencing analysis and verified that downregulating PADI2 and Olaparib combination treatment suppresses EMT and JAK2/STAT3 signaling pathway in A2780 and SKOV3 cells in vitro and in vivo.
Conclusions:
Downregulation of PADI2 and Olaparib combination treatment attenuated the proliferation, migration and invasion of A2780 and SKOV3 cells by inhibiting the EMT through JAK2/STAT3 signaling pathway.
Insights
Downregulating Peptidylarginine deiminase type II (PADI2) combined with Olaparib suppresses ovarian cancer cell proliferation, migration, and invasion by inhibiting EMT via the JAK2/STAT3 pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epithelial ovarian cancer (EOC) is a highly lethal gynecological malignancy.
- Peptidylarginine deiminase type II (PADI2) is implicated in the progression of various cancers, including ovarian cancer.
- Understanding the role of PADI2 in ovarian cancer (OC) is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the biological role and underlying mechanisms of PADI2 in ovarian cancer.
- To evaluate the combined effect of PADI2 downregulation and Olaparib treatment on ovarian cancer cells.
- To elucidate the signaling pathways affected by PADI2 modulation in ovarian cancer.
Main Methods:
- Gene expression analysis using GEPIA and ONCOMINE.
- Survival analysis via Kaplan-Meier plotter.
- In vitro assays including MTT, colony formation, EdU proliferation, wound healing, and Transwell assays.
- Transcriptome sequencing and Western blot for pathway analysis.
- In vivo studies using a nude mouse model.
Main Results:
- PADI2 is upregulated in ovarian cancer, with high expression correlating with poor prognosis.
- PADI2 knockdown inhibited proliferation, colony formation, migration, and invasion in A2780 and SKOV3 ovarian cancer cells.
- Combined downregulation of PADI2 and Olaparib treatment significantly attenuated cell viability, migration, and invasion.
- The combination treatment suppressed epithelial-mesenchymal transition (EMT) and the JAK2/STAT3 signaling pathway.
Conclusions:
- Downregulation of PADI2 in combination with Olaparib inhibits ovarian cancer cell proliferation, migration, and invasion.
- This therapeutic strategy acts by suppressing EMT through the JAK2/STAT3 signaling pathway.
- Targeting PADI2 offers a potential therapeutic avenue for ovarian cancer treatment, particularly in combination with PARP inhibitors like Olaparib.
Related Concept Videos
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


